Publication:
Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability

Placeholder

Organizational Units

Program

KU Authors

Co-Authors

N/A

Advisor

Publication Date

Language

English

Journal Title

Journal ISSN

Volume Title

Abstract

In this study, new co-amorphous drug systems were designed using a pharmacologically relevant combination to improve the solubility and dissolution of indomethacin. Combinations of indomethacin-paracetamol (IND-PAR) as an anti-inflammatory/pain killer, and indomethacin-nicotinamide (IND-NCT) for prevention of gastric ulcers caused by IND, were developed for co-amorphization. The effect of PAR and NCT on the solubility, supersaturation, and dissolution of the poorly soluble counterpart, IND, was investigated. PAR and NCT were found to enhance the solubility and supersaturation of IND in biorelevant medium (FaSSIF) and in FaSSIF blank. Differential scanning calorimetry (DSC) showed capability of IND-PAR and IND-NCT binary mixtures to form eutectic mixture. Powder X-ray diffraction and DSC indicated the formation of a homogenous co-amorphous system with single T-g value. Hydrogen bonding between IND and each of PAR and NCT were found to stabilize the co-amorphous systems as supported by FTIR studies. The intrinsic dissolution rate under sink conditions was improved over that of plain amorphous IND both in FaSSIF and FaSSIF blank. IND-PAR 2:1 and IND-NCT 1:1 were extremely stable and remained amorphous for 7 months at 25 degrees C, while all co-amorphous formulations were stable at least up to one month at 40 degrees C under dry condition. The present work demonstrates an improved approach to combine IND-PAR and IND-NCT as promising co-amorphous systems for potential therapeutical applications.

Source:

International Journal Of Pharmaceutics

Publisher:

Elsevier

Keywords:

Subject

Pharmacology, Pharmacy

Citation

Endorsement

Review

Supplemented By

Referenced By

Copyrights Note

0

Views

0

Downloads

View PlumX Details